Trans-aTTom: To offer more?

Watch Now Trans-aTTom: To offer more?

Neoadjuvant vs adjuvant approaches in early TNBC

Watch Now Neoadjuvant vs adjuvant approaches in early TNBC

Canadian Perspective on Overall survival (OS) in KATE2.

Watch Now Canadian Perspective on Overall survival (OS) in KATE2.

KEYNOTE-119: Phase 3 study of pembrolizumab versus single-agent chemotherapy for metastatic triple-negative breast cancer.

Watch Now KEYNOTE-119: Phase 3 study of pembrolizumab versus single-agent chemotherapy for metastatic triple-negative breast cancer.

Message from our Editor-in-Chief

Watch Now Message from our Editor-in-Chief